HS-10383

DRUG3 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Cough

Phase 1

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383

Jiangsu Hansoh Pharmaceutical Co., Ltd.Cough

Start: 2022-03-01End: 2022-06-30Target: 32Updated: 2022-07-01

A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383

Jiangsu Hansoh Pharmaceutical Co., Ltd.Cough

Start: 2023-06-14End: 2023-12-30Target: 48Updated: 2023-10-23

Phase 2

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

Not yet recruitingNCT06246565

Jiangsu Hansoh Pharmaceutical Co., Ltd.Cough

Start: 2024-03-01End: 2026-06-01Target: 276Updated: 2024-03-04